Adult Glioblastoma Clinical Trial
Official title:
A Phase I Study of CCI-779, and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme
This phase I trial is studying the side effects and best dose of temsirolimus when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma multiforme. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving temsirolimus together with temozolomide and radiation therapy may kill more tumor cells.
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose of temsirolimus when administered with temozolomide
in combination with radiotherapy followed by adjuvant temozolomide in patients with newly
diagnosed glioblastoma multiforme.
II. Assess and describe the adverse events associated with this regimen in these patients.
III. Evaluate the early response to therapy in these patients using an automated
morphological MRI change detector and physiological MRI techniques, including
diffusion-weighted imaging, perfusion-weighted imaging, and chemical shift imaging.
SECONDARY OBJECTIVES:
I. Determine the inhibition status of mTOR signaling pathways in peripheral blood
mononuclear cells in patients treated with this regimen.
II. Identify potential pharmacokinetic interactions between temozolomide and temsirolimus.
III. Correlate, preliminarily, survival, progression-free survival, and response with
pre-treatment tumor tissue molecular markers in these patients.
OUTLINE: This is a multicenter, dose-escalation study of temsirolimus. Patients are assigned
to 1 of 2 treatment groups.
GROUP 1: (temsirolimus with radiation and temozolomide) Patients receive temsirolimus IV
over 30 minutes once weekly. Beginning 7-10 days later, patients also receive oral
temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated
radiotherapy once daily, 5 days a week, for 6 weeks. Patients are evaluated 4-6 weeks after
completion of chemoradiotherapy. Patients with stable or responding disease proceed to
adjuvant therapy. Cohorts of 3-6 patients receive escalating doses of temsirolimus until the
maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at
which 2 of 3 or 2 of 6 patients experience a dose-limiting toxicity. At least 6 patients are
treated at the MTD.
GROUP 2: (radiation and temozolomide) Patients receive oral temozolomide daily and undergo
concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days
a week, for 6 weeks. Patients are evaluated 4-6 weeks after completion of chemoradiotherapy.
Patients with stable or responding disease proceed to adjuvant therapy.
ADJUVANT THERAPY: Beginning 4-6 weeks after the completion of chemoradiotherapy patients
receive oral temozolomide on days 1-5. Treatment repeats every 28 days for up to 6 courses
in the absence of disease progression or unacceptable toxicity.
Some patients undergo blood collection for immune monitoring and translational/pharmacologic
studies. After completion of study treatment, patients are followed periodically for 5
years.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02530502 -
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 1 | |
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT00238303 -
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00049387 -
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
|
Phase 1 | |
Completed |
NCT02227901 -
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT02015819 -
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
Active, not recruiting |
NCT02179086 -
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 2 | |
Recruiting |
NCT04573140 -
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
|
Phase 1 | |
Active, not recruiting |
NCT00823797 -
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
|
Phase 2 | |
Completed |
NCT00045565 -
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Completed |
NCT01977677 -
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT01648348 -
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00004262 -
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT01575275 -
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT01996527 -
3T MRI Biomarkers of Glioma Treatment Response
|
Early Phase 1 | |
Completed |
NCT01119599 -
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01103375 -
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
|
Phase 1 | |
Completed |
NCT00459381 -
Pazopanib in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
Terminated |
NCT00006773 -
Bortezomib in Treating Patients With Recurrent Glioma
|
Phase 1 |